1. Home
  2. TGTX vs LRN Comparison

TGTX vs LRN Comparison

Compare TGTX & LRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TGTX
  • LRN
  • Stock Information
  • Founded
  • TGTX 1993
  • LRN 2000
  • Country
  • TGTX United States
  • LRN United States
  • Employees
  • TGTX N/A
  • LRN N/A
  • Industry
  • TGTX Biotechnology: Pharmaceutical Preparations
  • LRN Other Consumer Services
  • Sector
  • TGTX Health Care
  • LRN Real Estate
  • Exchange
  • TGTX Nasdaq
  • LRN Nasdaq
  • Market Cap
  • TGTX 5.5B
  • LRN 6.3B
  • IPO Year
  • TGTX 1995
  • LRN 2007
  • Fundamental
  • Price
  • TGTX $33.20
  • LRN $63.80
  • Analyst Decision
  • TGTX Strong Buy
  • LRN Buy
  • Analyst Count
  • TGTX 4
  • LRN 4
  • Target Price
  • TGTX $54.75
  • LRN $129.25
  • AVG Volume (30 Days)
  • TGTX 2.2M
  • LRN 2.1M
  • Earning Date
  • TGTX 11-03-2025
  • LRN 10-28-2025
  • Dividend Yield
  • TGTX N/A
  • LRN N/A
  • EPS Growth
  • TGTX N/A
  • LRN 15.30
  • EPS
  • TGTX 2.78
  • LRN 6.34
  • Revenue
  • TGTX $531,898,000.00
  • LRN $2,475,117,000.00
  • Revenue This Year
  • TGTX $82.31
  • LRN $6.89
  • Revenue Next Year
  • TGTX $49.05
  • LRN $3.93
  • P/E Ratio
  • TGTX $11.98
  • LRN $10.01
  • Revenue Growth
  • TGTX 100.88
  • LRN 17.25
  • 52 Week Low
  • TGTX $25.28
  • LRN $61.89
  • 52 Week High
  • TGTX $46.48
  • LRN $171.17
  • Technical
  • Relative Strength Index (RSI)
  • TGTX 55.65
  • LRN 23.72
  • Support Level
  • TGTX $30.15
  • LRN $62.88
  • Resistance Level
  • TGTX $33.79
  • LRN $67.63
  • Average True Range (ATR)
  • TGTX 1.18
  • LRN 2.47
  • MACD
  • TGTX 0.29
  • LRN 2.51
  • Stochastic Oscillator
  • TGTX 87.33
  • LRN 18.68

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

About LRN Stride Inc.

Stride Inc is an American online educational company. It offers alternative programs to traditional on-campus schooling. It also operates state-funded virtual charter schools around the United States. The educational programs for K-12 students are usually monitored by parents and provide virtual classroom environments where teachers meet with students online, by phone, or in-person. The company's contractual agreements with various school districts to offer its curriculum programs provide a majority of the company's revenue. The company lines of business are Managed Public School Programs, Institutional and Private Pay Schools and Other.

Share on Social Networks: